<DOC>
	<DOCNO>NCT00720408</DOCNO>
	<brief_summary>The purpose study compare efficacy safety Prograf extend release ( XL ) plus MMF Prograf plus MMF steroid withdrawal de novo Liver transplant recipient</brief_summary>
	<brief_title>A Randomized Study Assess Safety Efficacy Prograf vs Prograf-XL de Novo Liver Transplant Recipients .</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Patient fully inform signed IRB approve informed consent form willing able follow study procedure Patient primary liver transplant recipient Patient must receive first dose XL Prograf ( IV tacrolimus subject unable tolerate oral study drug ) within 48 hour transplantation Female patient child bear potential must negative urine serum pregnancy test within 7 day prior transplant Patient previously receive receive organ transplant liver Recipient donor know seropositive human immunodeficiency virus ( HIV ) Patient receive liver transplant nonheart beat donor Patient receive ABO incompatible donor liver Patient current malignancy history malignancy ( within past 5 year ) , except hepatocellular carcinoma within UCSF Criteria 21 basal nonmetastatic squamous cell carcinoma skin treat successfully Patient fulminant hepatic failure , unless hemodynamically stable Patient uncontrolled concomitant infection , systemic infection require treatment ( except viral hepatitis ) , unstable medical condition could interfere study objective Patient severe diarrhea , vomit , active peptic ulcer gastrointestinal disorder may affect absorption tacrolimus Patient currently take take investigational drug 30 day prior transplant Patient know hypersensitivity tacrolimus , mycophenolate mofetil corticosteroid Patient pregnant lactate Patient unlikely comply visit schedule protocol , include protocol biopsy Patient form substance abuse , psychiatric disorder condition , opinion investigator , may invalidate communication investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Immunosuppressant</keyword>
	<keyword>Graft loss</keyword>
	<keyword>Combination drug therapy</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Open level method</keyword>
</DOC>